Discontinue use in patients w/ suspected ILD/pneumonitis. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Risk of photosensitivity reactions. Monitor liver function tests (eg, ALT, AST & total bilirubin) prior to start of treatment, every 2 wk during 1st 3 mth of treatment, then once a mth or as clinically indicated, w/ more frequent testing in patients who develop increased transaminases or bilirubin. Use of sunscreen or protective clothing; limit direct UV exposure during treatment. May affect ability to drive & use machines. Severe renal impairment. Men w/ women partners & women of reproductive potential should use effective contraception during treatment & for 1 wk after last dose. Pregnancy. Not to breastfeed during treatment & for 1 wk after last dose. Childn. Elderly.